Compare iShares International Treasury Bond ETF (IGOV) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares International Treasury Bond ETF vs Summit Therapeutics Inc — how do they compare? iShares International Treasury Bond ETF trades at $41.25, while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: iShares International Treasury Bond ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| IGOV | SMMT | |
|---|---|---|
52-Week High | $43.09 | $26.98 |
52-Week Low | $40.35 | $12.55 |
Market Cap | — | $12.06B |
Sector | — | Health |
Enterprise Value | — | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IGOV, an iShares International Treasury Bond ETF trading as a US stock, is priced at $41.19 with no recent change. Technical indicators show a bullish trend from moving averages, while oscillators are neutral. The asset faces pressure from global inflationary trends and rising interest rates, as highlighted in recent financial news.
The outlook for IGOV is cautious due to its high duration exposure amplifying risks from global rate hikes. Investment opportunities are limited by macroeconomic headwinds, with key risks including capital loss potential from prolonged energy issues and geopolitical tensions affecting international bond markets.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
